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Trojan Horse nanotheranostics with dual
transformability and multifunctionality for highly
effective cancer treatment
Xiangdong Xue 1, Yee Huang1,2, Ruonan Bo1, Bei Jia1, Hao Wu1, Ye Yuan1, Zhongling Wang1,3, Zhao Ma1,
Di Jing1,4, Xiaobao Xu1, Weimin Yu1,5, Tzu-yin Lin6 & Yuanpei Li 1
Nanotheranostics with integrated diagnostic and therapeutic functions show exciting
potentials towards precision nanomedicine. However, targeted delivery of nanotheranostics is
hindered by several biological barriers. Here, we report the development of a dual size/
charge- transformable, Trojan-Horse nanoparticle (pPhD NP) for delivery of ultra-small, full
active pharmaceutical ingredients (API) nanotheranostics with integrated dual-modal ima-
ging and trimodal therapeutic functions. pPhD NPs exhibit ideal size and charge for drug
transportation. In tumour microenvironment, pPhD NPs responsively transform to full API
nanotheranostics with ultra-small size and higher surface charge, which dramatically facilitate
the tumour penetration and cell internalisation. pPhD NPs enable visualisation of biodis-
tribution by near-infrared fluorescence imaging, tumour accumulation and therapeutic effect
by magnetic resonance imaging. Moreover, the synergistic photothermal-, photodynamic-
and chemo-therapies achieve a 100% complete cure rate on both subcutaneous and
orthotopic oral cancer models. This nanoplatform with powerful delivery efficiency and
versatile theranostic functions shows enormous potentials to improve cancer treatment.
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Nanotheranostics are engineered to simultaneously achievenon-invasive diagnosis and effective therapeutics in asingle nanoformulation1–3, which not only provides
promising potentials to real time visualise the ADMET (absorp-
tion, distributions, metabolism, elimination and toxicity)4 of the
nanomedicine, but also realises personalised, synergistic and
accurate therapeutic functions in a visualised manner. Although
promising, various biological barriers severely affect the delivery
efficiency of nanotheranostics into tumour tissue and cells. The
challenges mainly include: (i) undesirable circulation time in
blood; (ii) insufficient tumour accumulations due to inefficient
tumour vascular extravasation; (iii) limited tumour tissue pene-
trations due to the high interstitial fluid pressure and dense
extracellular matrix in the tumour microenvironment (TME); (iv)
ineffective cell internalisation and (v) inefficient intracellular drug
release. It is typically difficult to circumvent these obstacles
simultaneously. For instance, PEGylated nanoparticles could
lessen the opsonization5,6, and enhance their blood circulation
time7–9, therefore provide more chances for nanoparticles to take
advantages of enhanced permeability and retention (EPR) effect
in solid tumour10. However, the surface charge of the PEGylated
nanoparticles is close to neutral, which may mitigate the cell
internalisation, because of the inefficient interaction with the
negatively charged glycocalyx11 on the cell surface. The positively
charged nanoparticles are readily for cell uptake, but vulnerable to
the opsonization, and thereby, being rapidly cleared from blood.
The nanoparticles with smaller size have more chance to over-
come the interstitial transport hindrance and diffuse deeply into
tumour tissue12. However, they may be less desirable for tumour
vascular extravasation and favourable pharmacokinetics. In
addition, if the size of these nanoparticles is less than 5 nm, they
are likely to be excreted through kidney3. The nanoparticles with
a larger size may be able to circumvent the renal clearance and
have more advantages in tumour vascular extravasation, but their
tumour penetration is typically unsatisfactory.
Recently, several transformable nano-systems have been
developed to address the above-mentioned challenges13–16. For
instance, Chen’s group developed a gene delivery system to bal-
ance the surface charge issues for improvement of both tumour
accumulation and cell uptake17. Their group also developed
charge/size dual-transformable nanoparticles for overcoming a
variety of delivery barriers18. Wang’s group reported clustered
nanoparticles to realise size transformability, and significantly
improved the tumour penetration and anti-tumour efficacy19.
However, these strategies were mainly with mono-therapeutic
effect only, and lacked diagnosis capacities. Tumours are usually
heterogeneous, which often makes the treatments complicated,
and their responses to monotherapy approach are insufficient in
many clinical cases20. Construction of nanotheranostics with
synergistically combined multi-therapeutic functions and more
sophisticated design to circumvent the multiple biological barriers
for greatly improved delivery efficiency are highly desirable for
complete tumour elimination. Furthermore, the integrated ima-
ging functions of nanotheranostics offer unique capabilities in
non-invasively monitoring the real-time therapeutic delivery and
assessment of treatment outcomes.
Here, we report a dual size/charge- transformable, Trojan-Horse
nanoparticle (pPhD NP) for targeted delivery of ultra-small, mul-
tifunctional, full active pharmaceutical ingredient (API) nanother-
anostics with integrated dual-modal imaging and trimodal
therapeutic functions that enable to achieve multimodal imaging-
guided tumour eradication. As illustrated in Fig. 1, the construction
of pPhD NPs starts from a self-assembly of amphiphilic molecules
(PhD monomer), which are synthesised by the conjugation of two
API components, a hydrophobic photosensitizer (pheophorbide a,
Pa) and a hydrophilic anti-neoplastic drug (doxorubicin, DOX),
through hydrazone bonds that are cleavable at acidic intracellular
pH (pHi). The PhD monomers first assemble into micelle-like,
ultra-small, full API nanotheranostics, and then further assemble
into relatively large nanovehicles (upPhD NPs). Dual-aldehyde
terminated polyethylene glycol2000 (PEG-2CHO) is introduced and
reacted with the amine groups on the surface of upPhD NPs and
concurrently cross-link the nanoparticles through the formation of
Schiff base bonds that are cleavable at acidic extracellular pH (pHe)
of tumour, resulting in the final pPhD NPs. The pPhD NPs are
tailored to overcome various drug delivery barriers and integrate
versatile theranostic functions simultaneously in a single formula-
tion: (i) The PEGylation could significantly reduce the positive
surface charge to improve the blood circulation time, and con-
currently form intraparticle cross-linkages to stabilise the nano-
particles; (ii) The PEG surface could be responsively detached at
pHe of TME to release PhD-based nanotheranostics with ultra-
small size and highly positive surface charge, and thereby, drama-
tically improve the tumour tissue penetration and overall cell
internalisation; (iii) The hydrazone bond between Pa and DOX
could be cleaved at pHi inside the lysosomes of tumour cells to
further accelerate the drug release; (iv) The ultra-small nanother-
anostics with nearly 100% API contents (photosensitizer/chelator
and chemo-drug) could synergistically combine phototherapy and
chemotherapy to improve the efficacy; (v) The intrinsic optical- and
magnetic-resonance-imaging capabilities of Pa in the nanoparticles
could be used to visualise the real-time in vivo delivery and ther-
apeutic efficacy non-invasively.
Results
Construction and characterisations of PhD NPs. The PhD
monomers were synthesised by conjugating pheophorbide a (Pa)
and doxorubicin (DOX) through a pHi cleavable hydrazone bond
(Supplementary Figure 1). The results from mass spectrometry
and nuclear magnetic resonance (NMR) studies indicated that the
PhD monomers were successfully synthesised (Supplementary
Figure 2–5). The synthesis and characterisation of dual-aldehyde
terminated PEG2000 (PEG-2CHO), and its reaction with amine
groups on DOX was illustrated in Supplementary Figure 6–9. The
PhD monomers were first assembled into PhD NPs, then
PEGylated and cross-linked by PEG-2CHO through the forma-
tion of Schiff base, resulting in PEGylated PhD NPs (pPhD NPs,
as shown in Fig. 1). The particle morphology was observed by
TEM (Fig. 2a). The pPhD NPs were shown as spherical nanos-
tructures, in which hived hundreds of small dark dots. As illu-
strated in Fig. 1, this Trojan-Horse liked nano-architecture was a
secondary self-assembly of small PhD micelles through multi-
micelle aggregation21–24. The size distribution of pPhD NPs was
measured by dynamic light scattering (DLS). As shown in Fig. 2b,
pPhD NPs were around 79 nm, and the polydispersity index
(PDI) was 0.2. In pPhD NPs, the content of DOX was ~24.9%
(mass ratio) while that of photosensitizer (Phy, Phy is Pa with a
hydrazide pendant) was ~28.4% (mass ratio) (Supplementary
Figure 10). The critical aggregation concentrations (CAC) of
pPhD NPs were calculated to be 3 µM (Supplementary Figure 11).
The nanoparticle stability was monitored by incubating the pPhD
NPs in the presence of serum. As shown in Supplementary Fig-
ure 12, pPhD NPs retained their original size distribution for
2 weeks. The UV–vis spectra (Fig. 2c) of PhD monomers showed
elevated absorbance of DOX around 488 nm and Phy peak
around 412 and 670 nm, indicating the PhD monomer contained
both Phy and DOX. The fluorescence spectra (Fig. 2d) showed
that the emission of DOX was at ~590 nm, and that of Phy was at
~680 nm. While being conjugated together, the fluorescence of
DOX at 590 nm decreased, and that of Phy at 680 nm increased,
indicating a fluorescence resonance energy transfer may occur in
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PhD monomers. In nanoformulation (pPhD NPs), aggregation
caused quenched (ACQ) phenomenon25,26 dominated and
quenched both fluorescences of Phy and DOX (Fig. 2e).
Near-infrared imaging, photothermal and photodynamic effect
of pPhD NPs. Since porphyrin derivatives are intrinsically
suitable for near infrared imaging (NIRFI)27–29, the NIRFI
capacity of the PhD monomers and its nanoformulation (pPhD
NPs) was evaluated in an animal imaging system. The PhD
monomer exhibited excellent fluorescence signal (Fig. 2f), indi-
cating it was appropriate for NIRFI. The pPhD NPs showed very
low fluorescence due to the occurrence of ACQ, which was
consistent with the results from the fluorescence spectra (Fig. 2e).
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Fig. 1 Schematic illustration of the Trojan-Horse nanoparticles. Image illustration of the functionalities of the building blocks and construction of the Trojan-
Horse nanoparticles (pPhD NPs), and their capabilities to overcome a series of biological barriers through TME responsiveness, de-PEGylation/cross-
linkage, transformability, superior penetrations, enhanced cell internalisation, intracellular drug release for multimodal imaging and trimodality therapies.
Abbreviations: PDT photodynamic therapy, PTT photothermal therapy, NIRFI near-infrared fluorescence imaging, MRI magnetic resonance imaging, TME
tumour microenvironment, Red square denotes Phy, and blue circle denotes DOX, PhD pheophorbide a-hydrazone-doxorubicin, upPhD NPs unPEGylated
PhD NPs, pPhD NPs PEGylated PhD NPs, 1O2 reactive oxygen species
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Fig. 2g showed that the temperature of pPhD NPs increased to
around 50 °C upon laser irritation, demonstrating their excellent
photothermal property. Furthermore, the pPhD NPs could pro-
duce considerable reactive oxygen species (ROS) in a
concentration-dependent manner (Fig. 2h).
pH-stimulus drug release of pPhD NPs. The hydrazone bond
could be cleaved at pHi inside tumour cells30–32. Therefore, the
pPhD NPs were designed to release the drug under the stimula-
tion of acidic pH and/or laser. Firstly, the cleavage of the
hydrazone bond was proved by incubating PhD monomers in
pHi (pH 5.0) and subjected to liquid chromatography-mass
spectrometry (LC-MS). Hydrazone bond is well known to be
traceless reversible chemical bond31,33, and cleavage at hydrazone
bond will yield two original chemicals that were employed to
construct the PhD monomer. Hence, three peaks were expected
to appear in the total ion chromatography (TIC) spectrum,
including the peaks of Phy (~607 Da), DOX (~544 Da), and un-
cleaved PhD monomer (~1132 Da). As shown in Supplementary
Figure 13, the TIC spectrum exhibited three main peaks (upper
panel) and each peak corresponded to a mass spectrum (lower
panel). The doxorubicin was first eluted out (#1, 4.70 min), and
the corresponding mass spectrum showed peak at 544.1 Da; the
second peak was the PhD monomers (#2, 6.56 min), and was
correlated to 1132.5 Da in mass spectrum; and the last TIC peak
(#3, 8.54 min) was related to 607.2 Da, indicative of the Phy. The
LC-MS results supported that the PhD molecules can be cleaved
by pHi from hydrazone bond. Then, the accumulated drug
releasing pattern of pPhD NPs was shown in Fig. 2i. The nano-
particles were stable in physiological pH with minimal drug
release. The release could be significantly accelerated in acidic pH
(5.0, mimicking the lysosomes pH) that closed to pHi. While
triggered with both laser and acidic pH, the nanoparticles could
release the drug even faster and the accumulated drug release rate
reached nearly 80% within 48 h. The drug-releasing pattern
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supported that the pPhD NPs could stay stable in physiological
conditions, but effectively release the drug under specific stimuli
(pH and/or laser).
Size/charge dual-transformability of pPhD NPs. We hypothe-
sised that the ultra-small nanoparticles that constrained in pPhD
NPs would be released after the peeling of the PEG surface in the
TME, as the Schiff base used for PEGylation/cross-linkage was
ultrasensitive to pHe17,34. To prove this hypothesis, pPhD NPs
were incubated at pH 6.8 for different time, and their Trojan-
Horse liked behaviours were directly observed by TEM (Fig. 3a).
At the very beginning, pPhD NPs were stable, and able to
accommodate hundreds of ultra-small nanoparticles in the
Trojan-Horse liked nanostructure. While the pPhD NPs could
still be observed at 1 h, most ultra-small nanoparticles were
released. At 12 h, all ultra-small nanoparticles (~4 nm) were
released (Fig. 3a). The TEM micrographs demonstrated that the
pPhD NPs were stable enough to retain the ultra-small nano-
particles under normal physiological condition but could
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effectively release ultra-small nanoparticles in response to pHe in
TME. The changes in surface charges further confirmed the
PEGylation and de-PEGylation (Fig. 3b). Before PEGylation, the
nanoparticles (upPhD NPs, un-PEGylated PhD NPs) exhibited
strongly positive charge (43 mV). While after PEGylation, the
surface charge decreased to 12 mV. When the pPhD NPs were
treated at pH 6.8, the charge rebounded to 35mV. The results of
TEM and surface charge studies supported that pPhD NPs were
dual-transformable, both size and surface charge could be
transformed to desirable values that may be beneficial to superior
tumour penetration (ultra-small size) and enhanced cell uptake
(strong positive charge).
Transformability-enhanced cellular uptake, ROS production
and apoptosis in vitro. Furthermore, we investigated the benefits
of the dual-transformability of pPhD NPs in oral squamous cell
carcinoma 3 (OSC-3) cells. pPhD NPs (pH 7.4) and post-
transformed pPhD NPs (pre-treated in pH 6.8) were incubated
with OSC-3 cells to evaluate the transformability-enhanced cell
uptake. pPhD NPs incubated with cells in slightly acidic cell
culture medium (pH 6.8 medium) was also employed to explore
the benefits of dynamic transformability. As shown in Fig. 3c. the
post-transformed pPhD NPs and the dynamic transformed
groups both showed significantly enhanced cellular uptake than
the non-transformed nanoparticles. The cellular uptake results
indicated that the elevated surface charge could significantly
enhance the cellular uptake and the slightly acidic pHe would be
able to trigger this process as well. We then evaluated the ROS
production in OSC-3 cells and found that the post-transformed
nanoparticles (pPhD NPs at pH 6.8) produced significantly
higher amount of ROS in comparison to free photosensitizer
(Phy) and the nanoparticles at pH 7.4 (Fig. 3d and Supplementary
Figure 14). The cell apoptosis assays showed consistent results.
Post-transformed pPhD NPs exhibited more significant apoptosis
than their counterpart at pH 7.4 and other control groups (Fig. 3e
and Supplementary Figure 15).
Tumour penetrations and lysosome-colocalization of the pPhD
NPs. The pPhD NPs could transform to nanoparticles with ultra-
smaller size that may penetrate deeper in tumour tissue than the
particles with larger size. To prove it experimentally, pPhD NPs
and post-transformed pPhD NPs were incubated with OSC-3 cell
spheroids, respectively, and observed under confocal microscopy.
pPhD NPs incubated with cell spheroids in slightly acidic med-
ium (pH 6.8 medium) was also employed to explore the dynamic
transformability-enhanced penetration (Fig. 3f). In pPhD NPs
treated tumour cell spheroids, the fluorescence of DOX and Phy
were both distributed at the periphery at the first 3 h, then dif-
fused further at a prolonged incubation time (24 h). Upon
transforming into ultra-small nanoparticles (pPhD NPs at pH
6.8), the fluorescence signal spread much further than that at
neutral pH at the first 3 h, then diffused throughout the whole
tumour spheroid after 24 h incubation. The acidic medium
treatment also dynamically led to superior penetration of pPhD
NPs than that in neutral medium. This result indicated that the
pHe would be able to stimulate the transformability and the
resulting ultra-small nanoparticles could penetrate much deeper
into the tumour spheroids than the bigger nanoparticles. After
the nanoparticles have been ingested into the tumour cells, the
pPhD NPs were expected to release the drug (DOX) upon the
cleavage of hydrazone bonds by pHi inside the lysosomes. We
incubated pPhD NPs with OSC-3 cells and co-localised the
fluorescence of DOX (green) with lysosomes (red). As shown in
Fig. 3g, DOX showed large co-localisation areas with lysosomes,
indicating that our nanoparticles could release DOX in lysosomes,
in which the pHi enabled cleavage of the hydrazone bond.
In vitro controllable phototherapy of pPhD NPs. We then
irradiated a discrete area of OSC-3 cells pre-incubated with pPhD
NPs, and observed the laser-treated and non-treated cells
(Fig. 3h). Most of OSC-3 cells treated with pPhD NPs & laser
were dead as indicated by PI staining, while the cells incubated
with pPhD NPs without laser treatment, exhibited much less cell
death. As a control group, the PBS treated cells showed no
obvious cell death, in both regions exposed or not exposed to
laser. These results indicated that the phototherapy with pPhD
NPs was controllable, only impacted the region where the laser
was directed.
Synergistic effect of phototherapy and chemotherapy. The
synergistic effect of the chemotherapy and phototherapy of pPhD
NPs was evaluated. OSC-3 cells were incubated with different
concentrations of free photosensitizer (Phy), free chemother-
apeutic drug (DOX) and pPhD NPs, respectively, then treated
with or without laser (Fig. 3i). In the non-laser-treated group, free
Phy exhibited no obvious cytotoxicity while free DOX and pPhD
NPs showed notable anti-tumour efficacy. In the laser-treated
group, Phy exhibited enhanced efficacy comparing to the non-
laser-treated counterpart. The cell-killing effect of DOX remained
at a similar level. It is worth noting that the pPhD NPs treated
group showed the most effective anti-tumour activity against
OSC-3 cells among all the groups with or without laser treatment.
We then calculated the combination index (CI)35,36 of the pho-
totherapy and chemotherapy based on Fig. 3i, which demon-
strated that these therapeutic modalities showed excellent
synergistic effect to kill the cancer cells (Fig. 3j and Supplemen-
tary Table 1).
Pharmacokinetics (PK) profiles of the pPhD NPs. The PEGy-
lation can shield the highly positive surface charge and form the
interparticle cross-linkage which may greatly affect the blood
circulation and tumour accumulation of pPhD NPs. Therefore,
Fig. 3 In vitro evaluation of pPhD NPs. a TEMmicrographs illustrated the Trojan-Horse liked behaviours of pPhD NPs (50 µM) at pH 6.8. The scale bar of 0
h micrograph is 10 nm; 1 h and 12 h are 30 nm. b Surface charge changes (n= 3) of the pPhD NPs (50 µM) before/after PEGylation and de-PEGylation. De-
PEGylation was realised by incubated pPhD NPs at pH 6.8. c Cell uptake (n= 3) of the pPhD NPs (10 µM) before and after being transformed at pH 6.8; the
medium was adjusted to pH 6.8 to assess the dynamic transformation-enhanced cellular uptake. d ROS production of the nanoparticles in OSC-3 cancer
cells (n= 3). e Apoptosis of OSC-3 cells (n= 3). In ROS and apoptosis analysis, the concentrations of materials, including photosensitizer, free DOX and
nanoparticles, were all set as 10 µM. f Cell penetration evaluated in tumour cell spheroids. the medium was adjusted to pH 6.8 to assess the dynamic
transformation-enhanced superior penetration. The scale bar is 100 µm. g Lysosomes co-localisation illustrated that drug was released in lysosomes. The
scale bar is 20 µm. h Laser-directed phototherapeutic effect on cells, the yellow lighting symbol indicates laser-treated area. The live cells were indicated by
DIC6(3), the dead cells stained with PI. i Cell viabilities of OSC-3 cells by treated with different concentrations of Phy, DOX and pPhD NPs, with or without
light irradiation (n= 3). j Combination index (CI) of chemotherapy and phototherapy with pPhD NPs towards OSC-3 cells. *p < 0.05; **p < 0.01; ***p <
0.001. All error bars are presented as standard deviation
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the un-PEGylated PhD NPs (upPhD NPs as illustrated in Fig. 1)
were introduced as control to elucidate the influence of PEGy-
lation on the PK and biodistribution. The morphology and size
distributions of upPhD NPs were first investigated. As shown in
Supplementary Figure 16, the upPhD NPs exhibited a similar
morphology to pPhD NPs, which showed bigger nanoparticles
that constructed with clusters of small-dots, but without PEG
corona wrapping around. The hydrodynamic size was around
100 nm and slightly larger than pPhD NPs. Then, the PK profiles
of pPhD NPs was determined in jugular vein cauterised rats by
comparing with the equivalent dose of upPhD NPs and free
DOX. As shown in Supplementary Figure 17 and Supplementary
Table 2, two nanoformulations, including pPhD NPs and upPhD
NPs, possessed similar T-half (α) that was much longer (7.2
times) than free DOX, indicating that the nanoformulation
enabled to largely mitigate the blood clearance of the che-
motherapeutic drugs. The PEGylated nanoparticles (pPhD NPs)
showed the longest second phase circulation half-time (T-half (β),
1440 min), which provided a long time window for tumour
accumulation. The pPhD NPs also exhibited bigger AUC and
higher C-max than un-PEGylated ones (upPhD NPs), which
supported that the PEGylation improved the blood circulation
time and minimised the opsonization effect. For upPhD NPs, the
C-max was close to free DOX but much lower than pPhD NPs,
indicating that substantial amounts of un-PEGylated nano-
particles suffered from opsonization at the first 2 min after i.v.
administration, causing the rapid elimination of the nano-
particles. In contrast, free DOX showed weaker PK profile
(including C-max, AUC and T-half) than both nanoformulations.
Biodistribution in orthotopic oral tumour models by NIRFI.
Oral cancer commonly occurs at sites of the lips, tongue, cheeks,
floor of the mouth, hard and soft palate, sinuses, and pharynx,
and is readily accessible to light. It represents an excellent clinical
situation for the potential applications of pPhD NPs developed in
this study. We then investigated whether the PEGylation could
greatly improve biodistribution profile in orthotopic oral cancer
models established by implantation of OSC-3 cells into the lips of
nude mice. The in vivo NIRFI of upPhD NPs and pPhD NPs were
conducted on orthotopic oral tumour model. As shown in Sup-
plementary Figure 18 & 19, both nanoparticles preferentially
accumulated at tumour site. The ex vivo NIRFI further confirmed
that their higher accumulation in tumours than in normal organs
(Fig. 4a). The fluorescence signal of pPhD NPs in the centre of the
tumour was much stronger than that of upPhD NPs. The
quantitative fluorescence comparison (Fig. 4b) showed that pPhD
NPs exhibited significantly higher tumour accumulation than its
un-PEGylated counterpart (upPhD NPs).
Time-dependent tumour accumulation of pPhD NPs by MRI.
In contrast to optical imaging, MRI has superior features, like
deeper penetration. MRI also offers excellent spatial and anatomic
resolution. As pPhD NPs have intrinsic capability to chelate
manganese (II) ion (Mn2+) (Fig. 4c), we could conveniently
utilise MRI to visualise the tumour accumulation of the nano-
particles in real time. The UV–vis and fluorescence spectra in
Supplementary Figure 20 supported that the Mn2+ was success-
fully chelated to PhD molecules37,38. The T1 MRI contrast of
PhD NPs was concentration-dependent (Fig. 4d) and the relax-
ivity (r1) of Mn2+ chelated PhD NPs was calculated to be 2.89
mM−1 S−1. The dynamic contrast-enhanced MR images in
orthotopic oral cancer models were displayed in Fig. 4e. The T1-
weighed MR signal at tumour sites showed a time-dependent
manner with the MR signal intensity increased after injection of
the nanoparticle, reached a peak at 24 h, then gradually decreased.
Interestingly, the MR signals of pPhD NPs were significantly
higher than the non-transformable nanoformulation (upPhD
NPs) at 4, 8, 24, 48, and 72 h post-injection (Fig. 4e, f). The MR
signals of pPhD NPs retained at tumour sites at a considerable
level for up to 72 h. The PK, NIRFI and MRI studies demon-
strated that the PEGylated cross-linkage greatly contributed to the
better in vivo performance of pPhD NPs, such as the longer blood
circulation and better tumour accumulation.
Investigation of the in vivo phototherapeutic effects. The
phototherapeutic effects of pPhD NPs were investigated on the
orthotopic oral cancer model. As shown in Fig. 4g, the
photosensitizer-harboured groups all exhibited better photo-
thermal effect than PBS control as measured by the temperature
rises at the tumour site. Among these groups, pPhD NPs exhib-
ited highest heat generation, and the temperature of the tumours
treated with pPhD NPs increased about 24 °C. Fig. 4h, i displayed
the photodynamic effects, in which pPhD NPs treated group
produced significantly more ROS production than other three
groups.
Phototherapeutic outcomes of pPhD NPs visualised by MRI.
As Mn2+ chelated pPhD NPs possessed intrinsic capacity as a
MRI contrast agent, the Mn2+ chelated pPhD NPs was i.v.
injected into orthotopic oral tumour-bearing mice to in situ
monitor their phototherapeutic outcomes by MRI (Fig. 4j). The
T1 MRI signal dramatically increased at 24 h after the adminis-
tration of pPhD NPs. We then applied two doses (at 24 and 48 h
post-injection) of laser to trigger the phototherapeutic effect, and
the orthotopic oral tumour was continuously monitored for
changes in size and morphology. In the MR images, the tumour
shrunk extensively at 72 h and became smaller and smaller with
time elapse. The majority of tumour was ablated at 7 days (168 h)
of post-injection. The MRI visualisation showed promising merits
for evaluation of the therapeutic effects that cannot be observed
by naked eyes, especially for a tumour that cannot be directly
reachable.
In vivo therapeutic effects of pPhD NPs. We further performed
systematic treatment studies in both subcutaneous and orthotopic
tumour models to verify the synergistic therapeutics and superior
efficacy of pPhD NPs. The OSC-3 cells were implanted to two
positions of the flanks or lips of nude mice to establish sub-
cutaneous and orthotopic tumour models, respectively. After
tumour formation at 15 days, the mice were randomly assigned
into 5 groups (n= 6): control (PBS), free drug (DOX), free
photosensitizer (Phy), un-PEGylated PhD NPs (upPhD NPs) and
PEGylated PhD NPs (pPhD NPs). The experimental design and
workflow of the animal studies were shown in Supplementary
Figure 21. All tumour-bearing mice were treated once per week
for three consecutive weeks by i.v. administration. In sub-
cutaneous models (mice bearing two tumours), the right tumours
that treated with photosensitizer-harboured materials were sub-
jected to laser exposure (0.4W cm−2, 3 min), and the left-side
tumours were not treated with laser to evaluate the efficacy of
chemotherapy alone (Fig. 5a). In the orthotopic models, all
tumours treated with photosensitizer-harboured materials were
treated with laser (Fig. 5b). The laser treatments were given twice
at 24 and 48 h after the i.v. injection. Tumour volumes and body
weights were measured throughout the treatments. The changes
in tumour volume of the subcutaneous model were shown in
Fig. 5c. Since the oral cancer is highly malignant, the PBS and free
photosensitizer (without laser) groups didn’t exhibit obvious anti-
tumour efficacy. The tumour grew fast and all mice in these two
groups were sacrificed (considered dead) due to the oversized
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Fig. 4 In vivo evaluation of pPhD NPs in orthotopic oral cancer models. a NIRFI images and b quantitative fluorescence with statistical analysis of the
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ROS probe, CellROX. Pre denotes the NIRFI before CellROX treatment; Post means the NIRFI after CellROX indication. j Phototherapeutic effect monitored
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tumours within 2 weeks. The free photosensitizer with laser (Phy
+ L) and free chemo-drug (DOX) exhibited moderate anti-
tumour activity but could not slow down the tumour growth. The
nanoformulation groups without laser (upPhD NPs and pPhD
NPs) showed considerable anti-tumour efficacy than free chemo-
drugs, suggesting that our nanoparticles could improve drug
efficacy. The group of upPhD NPs with laser (upPhD NPs+ L)
showed more effective tumour inhibition and effectively pre-
vented the tumour progress. Most interestingly, the PEGylated
nanoparticles (pPhD NPs+ L) exhibited exceptional anti-tumour
efficacy, with 100% complete cure rate (Fig. 5d), which was much
higher than the laser-treated un-PEGylated nanoparticles (50%),
and other control groups (0%). The best anti-tumour efficacy of
pPhD NPs+ L group was further demonstrated in orthotopic
tumours (Fig. 5e), which achieved 100% complete cure rate as
well (Fig. 5f). The tumour images of subcutaneous and orthotopic
models that treated by pPhD NPs+ L (Fig. 5g, h) and upPhD
NPs+ L (Supplementary Figure 22 & 23) further indicated the
superiority of the PEGylation. H&E staining was utilised to
evaluate the phototherapeutic effect of free photosensitizer (Phy),
un-PEGylated nanoparticles (upPhD NPs) and PEGylated
nanoparticles (pPhD NPs) in tumour tissue compared with the
PBS group. As shown in Fig. 5i, all the phototherapy groups
caused different extent of tumour tissue damage, such as cellular
destruction and necrosis, in which the pPhD NPs induced the
largest areas of damage in treated tumour tissue. Fig. 5j showed
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NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06093-5 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3653 | DOI: 10.1038/s41467-018-06093-5 | www.nature.com/naturecommunications 9
the body weights changes of the mice along the duration of the
treatments. DOX-induced obvious body weights loss after the
second dose of treatment; pPhD NPs did not exhibit systemic
toxicity, since the mice gained body weights during the treatment.
Further investigation of transformability and functionalities.
We then introduced more control groups, such as non-
transformable pPhD NPs (NT-pPhD NPs), nanoformulation of
DOX (Doxil) and pPhD NPs with low laser dose, to further
investigate the dual-transformability, chemotherapeutic delivery
and photodynamic therapy alone of pPhD NPs, respectively. The
non-transformable pPhD NPs (NT-pPhD NPs) were developed
by introducing non-cleavable chemical bonds between the PEG
and nanoparticles as a more appropriate non-transformable
control. The NT-pPhD NPs were fabricated by following the
same procedures for the preparation of pPhD NPs, except that
the PEG-2CHO was replaced by PEG-2COOH NHS ester (Sup-
plementary Figure 24). The PEG-2COOH NHS ester reacted with
the amine groups on the surface of upPhD NPs and formed non-
cleavable amide bonds. Such PEGylation could not be detached,
and thus the resulting nanoparticles were not transformable. The
morphology and size distribution of NT-pPhD NPs were shown
in Fig. 6a, NT-pPhD NPs presented similar morphology as pPhD
NPs and exhibited similar hydrodynamic size at ~87 nm. The
dual-transformability was also investigated (Fig. 6b), neither the
size nor the surface charge was changed after being stimulated by
pHe (pH 6.8). The building blocks, morphology, surface mod-
ification, size distribution and surface charge of NT-pPhD NPs
were very similar to these of pPhD NPs, indicating that the NT-
pPhD NPs were an ideal control to elucidate the importance of
dual-transformability in vivo. After the NT-pPhD NPs were
prepared, a new set of animal studies were conducted to evaluate
the anti-tumour efficacy of the NT-pPhD NPs, Doxil and pPhD
NPs (with lower laser dose) in subcutaneous and orthotopic oral
cancer models. Followed the same protocol that used in Fig. 5, the
mice were randomly assigned into 5 groups (n= 6): PBS, Doxil,
NT-pPhD NPs, pPhD NPs and pPhD NPs with low laser dose.
The low laser dose was set to 0.2W cm−2 to generate PDT
dominant effect as reported previously39. The total laser power
was kept at the same level for the low dose (0.2W cm−2, 6 min)
and high dose groups (0.4W cm−2, 3 min). In subcutaneous
model (Fig. 6c), all the tumours in PBS group grew fast and the
mice died within two weeks. The Doxil exhibited excellent anti-
tumour activity and could effectively slow down the tumour
growth. The efficacy of chemotherapeutic function alone of pPhD
NPs without laser irradiation was comparable to that of Doxil (no
statistically significant difference) and such monotherapy could
effectively slow down the tumour progress. The effectiveness of
pPhD NPs can be ascribed to their unique dual-transformability.
Although they were very similar to pPhD NPs except the trans-
formability, NT-pPhD NPs only showed marginal efficacy, which
was ascribed to their limited penetration in tumours. We further
conducted microscopic imaging studies at tissue level to support
this claim. As shown in Fig. 6g, NT-pPhD NPs only stayed in the
periphery of the tumour blood vessels. In comparison, the pPhD
NPs showed superior tumour penetration and lit up the tissue
throughout the tumour. The anti-tumour efficacy and tissue
penetration combined to support that the transformability of
nanoparticles greatly contributed to the efficacy. The photo-
therapy could be introduced to further enhance the efficacy by
applying laser irradiation on the tumours. The laser treatment
extensively enhanced the anti-tumour efficacy of NT-pPhD NPs,
and the tumour shrunk to smaller size, and one mouse in this
group was completely cured (Fig. 6d). The pPhD NPs showed
exceptional efficacy, and all the tumours were completely ablated
(CCR is 100%), which was dramatically more effective than NT-
pPhD NPs (Fig. 6d). The remarkable improvements of laser-
induced anti-tumour efficacy were ascribed to the extremely
effective PTT. As shown in Supplementary Figure 25, the laser
treatment elevated the temperature for more than ~17 °C in NT-
pPhD NPs and ~22 °C in pPhD NPs treated tumours, such
feverish temperatures were strong enough to ablate the tumour
tissue. Since the PTT at high laser dose was extremely powerful
which could completely deluge the PDT and chemotherapy, we
introduced a low laser dose treatment (0.2W cm−2, 6 min) to
pPhD NPs to evaluate the combination of the chemo- and pho-
todynamic- therapy. Such low laser dose only led to similar
photothermal effect to PBS group with 0.4W cm−2 laser (Sup-
plementary Figure 25), which yielded very limited efficacy on the
tumours (PBS+ L in Fig. 6c). Due to the presence of photo-
sensitizer, this low laser dose still elicited abundant ROS pro-
duction for PDT (Supplementary Figure 26). As shown in Fig. 6c,
the PDT alone enabled to extensively improve the efficacy of
pPhD NPs by comparing with the non-laser-treated pPhD NPs
and Doxil groups, supporting that PDT played a significant role
in the anti-tumour activities. In the orthotopic oral cancer model,
each group showed similar efficacy as that in subcutaneous model
(Fig. 6e). Doxil effectively slowed down the tumour progress; NT-
pPhD NPs showed excellent anti-tumour efficacy due to the
strong PTT effect; and pPhD NPs with high laser dose exhibited
the best anti-tumour efficacy and achieved 100% CCR (Fig. 6f).
The PDT and chemotherapy of pPhD NPs (0.2W cm−2, 6 min)
resulted in excellent anti-tumour efficacy, which were much
effective than Doxil. With the introduction of control groups,
such as NT-pPhD NPs, Doxil and pPhD NPs (0.2), we systemi-
cally elucidated the benefits of the dual-transformability, che-
motherapeutic delivery and role of the PDT alone for tumour
treatments of the pPhD NPs. The body weight for all treatment
group (Fig. 6h) was similar to that of PBS group, indicating that
these treatment groups exhibited no obvious toxicity in mice.
Systemic toxicity evaluations of pPhD NPs. The in vivo toxicity
to the main organs was evaluated by monitoring hematoxylin &
eosin (H&E) staining. The lesion of major organs was evaluated
by H&E staining (Supplementary Figure 27). DOX showed
obvious liver and heart toxicity, the striated muscle of heart
disappeared. All other groups didn’t exhibit distinguishable
abnormality, indicated that our nanoformulation could exten-
sively decrease the systemic toxicities of chemotherapeutic drugs.
Discussion
In this work, we developed dual-transformable, Trojan-Horse
nanoparticles (pPhD NPs), which enabled efficient delivery of
ultra-small, full API and multifunctional nanotheranostics for
cancer imaging and therapy. This nanoplatform was demon-
strated to have integrated highly efficient drug delivery functions
as well as synergistic trimodality therapeutic and dual-modal
imaging functions in one simple formulation. The pPhD NPs
possessed larger size and slightly positive charge with intraparticle
cross-linkages under normal physiological conditions and could
be responsively transformed to ultra-small nanotheranostics with
strongly positive charge in TME. The initial state of the nano-
particles with PEG surface was beneficial to the drug delivery in
blood vessel. Both post-transformed and dynamically trans-
formed nanoparticles enabled to improve the tumour cell uptake
and tumour interstitial penetrations, because of the strongly
positive charge and the ultra-small particle size. These features
endowed our nanoparticles with excellent capability to system-
atically circumvent the sequential biological barriers which had
hindered the drug delivery. We directly observed the size
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transformability by TEM, and validated the elevated cell uptake,
enhanced tumour accumulation and superior penetration of
pPhD NPs. The in vivo therapeutic studies supported that the
PEGylated and transformable nanoparticles could greatly
improve the therapeutic effect over the non-PEGylated and non-
transformable nanoparticles. Furthermore, the versatile ther-
anostic functions of pPhD NPs are highly valuable for cancer
treatment. In comparison with the commercially available and
well-developed Doxil, pPhD NPs showed comparable che-
motherapeutic effect as a monotherapy approach in OSC-3 oral
cancer model. When the PDT was introduced by using low dose
of laser, pPhD NPs were more efficacious than Doxil. When
photothermal therapy was involved by using high dose of laser,
the efficacy of pPhD NPs overwhelmed all other treatments,
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including Doxil. In comparison with other reported non-
PEGylated full API nanoparticles thus far21,40–42, pPhD NPs
yielded 100% CCR and showed better anti-tumour efficacy, due
to their excellent multimodal therapeutic functions, PEGylated
cross-linkage and dual-transformability. By comparing with the
multimodal full API nanoparticles that we developed, such as
upPhD NPs in this work and PaIr NPs43, the anti-tumour efficacy
of pPhD NPs was also superior, which can be ascribed to their
excellent dual-transformability and PEGylated cross-linkage.
pPhD NPs could be conveniently prepared by simply using bio-
compatible PEG as the only excipient, the DOX and Pa as the
APIs. We utilised simple materials, but integrated versatile
functionalities in one single smart nanoplatform. With the simple
introduction of PEG, we realised dual-transformability, which
could sophisticatedly overcome the drug delivery barriers and
largely enhance the anti-tumour efficacy. The dual-transformable,
Trojan-Horse nanoparticles integrated trimodality therapeutic
functions in a single formulation, including photothermal-,
photodynamic- and chemotherapies. These treatment modalities
are complementary and synergistic. The phototherapy provides
an immediate, extensive tumour abrogation, and is highly useful
to treat chemo-resistant tumours44,45. While the chemotherapy
can provide sustainable therapeutic effect and is suitable to treat
tumours that are beyond the reach of the light. In the in vivo
therapeutic studies, the pPhD NPs with laser-treated tumour were
completely cured in both orthotropic and subcutaneous models.
Furthermore, our nanoparticles were intrinsically useful for dual-
modal imaging (NIRFI/MRI) and realised the nanoscale inte-
gration of imaging and therapeutic functions. The in vivo ther-
apeutic delivery, the time-dependent tumour accumulation and
the tumour response could be conveniently visualised by these
imaging modalities. These highly integrated theranostic functions
are very useful for individualised adjustment of treatment toward
precision nanomedicine.
This transformable, Trojan-Horse liked nanoplatform with
integrated powerful delivery efficiency and versatile theranostic
functions are expected to open a broad range of possibilities to
improve cancer management. It will also inspire other scientists
to develop next generation smart nanomaterials for a variety of
biomedical applications.
Methods
Materials and instruments. Pheophorbide a was bought from Santa Cruz Bio-
technology (TX, USA). Doxorubicin was purchased from LC Laboratories (MA,
USA). Doxil (2 mg mL−1) was purchased from Janssen Pharmaceutica (NV, USA).
Hydrazine, (1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide hydrochloride)
(EDC), N-hydroxysuccinimide (NHS), N, N′-Dicyclohexylcarbodiimide (DCC), 4-
Dimethylaminopyridine (DMAP), 2′,7′-Dichlorofluorescin diacetate (DCF-DA),
MnCl2 and all solvents were purchased from Sigma-Aldrich (MO, USA). Singlet
oxygen sensor green (SOSG), LysoTracker Deep Red and CellROX were purchased
from Thermo Fisher Scientific Inc. The synthetic compounds were analysed by
Bruker UltraFlextreme matrix-assisted laser desorption/ionisation time of flight
mass spectrometry (MALDI-TOF-MS), Thermo Electron LTQ-Orbitrap XL
Hybrid electrospray ionisation mass spectrometry (ESI-MS) and 600MHz Avance
III nuclear magnetic resonance (NMR) spectrometer (Bruker, German). Trans-
mission electron microscopy (TEM) was performed on a Talos L120C TEM (FEI)
with 80 kV acceleration voltage. The in vitro laser treatments were conducted
under light source that with broader covering area (Omnilux new-U). Cell fluor-
escence images were captured with a confocal laser scanning microscopy (CLSM,
LSM810, Carl Zeiss). The magnetic resonance imaging (MRI) was conducted on a
Biospec 7 T MRI scanner (Bruker, German). Apoptosis and cell ROS production
were evaluated by a BD Fortessa 20 colour flow cytometry. Hydroxylated Poly-
ethylene glycol 2000 (PEG2000) was purchased from Laysan Bio Inc (AL, USA).
Synthesis of pheophorbide a-hydrazide (Phy). 594 mg pheophorbide a (~1
mmol), 383 mg EDC (2 mmol) and 230 mg NHS (2 mmol) were dissolved in 20 mL
dichloromethane (DCM), and vigorously stirred at room temperature for 30 min.
Then 188 µL anhydrous hydrazine (6 mmol) was added into the reaction system.
The reaction was under vigorously stirring at room temperature for another 4 h.
Then, the pheophorbide a-hydrazide (Phy) was extracted from the reaction system
with DCM against water. The yield was ~83%. HRMS: m/z M+ [H]+ was
607.3010 Da. 1H-NMR (DMSO-d6, 600MHz): δ 9.69 (s, 1H), 9.33 (s, 1H), 8.90 (s,
1H), 8.16 (dd, J1= 17.4 Hz, J2= 11.4 Hz, 1H), 6.42 (s, 1H), 6.37 (d, J= 18.0 Hz,
1H), 6.37 (d, J= 11.4 Hz, 1H), 4.58 (m, 1H), 4.05 (m, 1H), 3.84 (s, 3H), 3.80 (s,
1H), 3.63 (m, 6H), 3.41 (s, 3H), 3.12 (s, 3H), 2.25 (m, 2H), 2.00 (m, 1H), 1.80 (d, J
= 7.8 Hz, 2H), 1.60 (m, 4H).
Synthesis of pheophorbide a-hydrazide-doxorubicin (PhD). 121.4 mg Phy (0.2
mmol) and 58 mg doxorubicin hydrochloride (0.1 mmol) with a drop of TFA (20
µL) were dissolved in 10 mL methanol and stirred overnight under 50 °C. The
target compound (PhD) was purified by column chromatography. The yield was
~42%. HRMS: m/z M+ [H]+ was 1132.4704 Da. 1H-NMR (DMSO-d6, 600MHz):
δ 10.26 (s, 1H), 9.63 (s, 1H), 9.20 (s, 1H), 8.16 (s, 1H), 8.01 (dd, J1= 18.0 Hz, J2=
12.0 Hz, 1H), 7.38 (m, 2H), 7.13 (d, J= 6.6 Hz, 1H), 6.28 (t, J= 12.6 Hz, 1H), 6.04
(d, J= 10.8 Hz, 1H), 5.76 (s, 2H), 5.66 (s, 1H), 5.22 (s, 1H), 4.90 (s, 1H), 4.50 (m,
2H), 3.99 (s, 2H), 3.87 (m, 2H), 3.77 (s, 3H), 3.69 (s, 3H), 3.62 (s, 3H), 3.58 (m.
3H), 3.31 (m, 6H), 3.18 (m, 1H), 3.06 (s, 2H), 2.55 (s, 1H), 1.91 (m, 1H), 1.72 (d, J
= 7.8 Hz, 2H), 1.61 (t, J= 7.8 Hz, 3H), 1.2 (m, 5H), 0.9 (m, 4H).
Synthesis and characterisation of dual-aldehyde terminated PEG. 570 mg 4-
Formylbenonic acid (5 mmol) and 206 mg DCC (7 mmol) were dissolved in
anhydrous (DCM). The mixture was stirred at 0 °C for 30 min until plenty of white
precipitates were observed. Then, 1000 mg hydroxylated PEG2000 (0.5 mmol) and
73 mg DMAP (0.6 mmol) in 10 mL anhydrous DCM was added. The resulting
mixture was stirred at ambient temperature for 24 h. The dual-aldehyde terminated
PEG was purified by precipitation via cold ether, and further dialysed with a
dialysis tube (MWCO is 1000 Da). The solution was then lyophilised. The MALDI-
TOF MS showed obvious spectra shift after dual-aldehyde was introduced. The
yield was ~87%. 1H-NMR (DMSO-d6, 600MHz): δ 10.13 (s, 2H), 8.17 (d, J= 0.84,
4H), 8.07 (d, J= 0.84, 4H), 4.45 (m, 4H), 3.79 (m, 4H), 3.63 (m, 4H), 3.55 (m, 4H),
3.51 (m, 164H).
Preparation and characterisation of PEGylated PhD NPs (pPhD NPs). The
nanoparticles were prepared by the following typical re-precipitation method25,46.
Briefly, 50 mmol PhD DMSO solution was firstly made, and 2 µL PhD solution was
then dropped into 998 µL Milli Q water under sonication, followed by a 3~5 s
vortex, resulting in the unPEGylated PhD NPs. Then, 100 µM dual-aldehyde ter-
minated PEG were added, and stirred under ambient temperature for 48 h,
resulting in the the pPhD NPs. The size distributions, PDI and surface charge of
the nanoparticles were carried on with a DLS (Zetasizer, Nano ZS) from Malvern
Instruments Ltd (Worcestershire, UK.). The morphology of NPs was observed by a
Talos L120C TEM (FEI) with 80 kV acceleration voltage. The TEM samples were
prepared by dropping aqueous nanoparticle solution (50 µM) on copper grids and
naturally dried under room temperature.
Mn2+ chelation of pPhD NPs. Mn2+ chelation was conducted by following the
published method37. In brief, 24.3 mg Phy (40 μmol) with five times of MnCl2
(25.2 mg, 200 μmol) were dissolved in 2 mL anhydrous methanol, then 200 µL
pyridine was added. The reaction system was under vigorous agitation and refluxed
for 2 h. The chelated Phy was purified by funnel separation (DCM against water)
for five times. The un-chelated Mn2+ dissolved in Milli Q water and was removed.
The Mn2+ chelated Phy distributed in organic layer (DCM), and was dried with a
rotavapor. Then, the manganese ion chelated Phy was employed to synthesise PhD
monomers and fabricate the pPhD NPs by following the procedures mentioned
above.
Optical measurements. The UV–vis spectra were collected with a UV–vis spec-
trometer (UV-1800, Shimadzu). For all materials and compounds, the absorbance
was collected under a range of 200–800 nm. The fluorescence spectra were obtained
by a fluorescence spectrometer (RF-6000, Shimadzu). The excitation and emission
bandwidths were both set as 5.0 nm, and the data interval was 1 nm. For Phy, the
excitation of 412 nm was used, while the emissive band was scanned from 432 to
800 nm. For DOX, the excitation was 488 nm, while the emission scanning ranged
from 508 to 800 nm. To measure the fluorescence properties of PhD monomer and
nanoformulation, both excitations were employed. For optical measurements, the
quartz cuvettes were with 1 mm path length.
Stability of pPhD NPs in serum. 100 µL pPhD NPs were incubated in 10% foetal
bovine serum and kept in a cell culture incubator at 37 °C. The hydrodynamic size
of the nanoparticles was continuously monitored by DLS.
CAC of pPhD NPs. Pyrene molecules were employed as an indicator to determine
the CAC of nanoparticles by comparing the fluorescence of their third and the first
emissive peaks (I3/I1). First, pPhD NPs were diluted into different concentrations
(0.01, 0.05, 0.1, 0.5, 1, 5, 10 and 50 µM); then, 999 µL pPhD NPs of each dilution
was incubated with 1 µL pyrene acetone solution (0.1 mM) at 37 °C for 2 h. The
fluorescence spectra of pyrene (excitation is 335 nm) in different pPhD NPs
dilutions were recorded. The fluorescence intensity ratio (I3/I1) of the third and
first emissive peaks were measured for CAC calculation.
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Near-infrared fluorescence imaging (NIRFI) of pPhD NPs. 10 µL PhD mono-
mers and pPhD NPs with varied concentrations were dropped on a transparent
film respectively, and put in the NIRFI chamber, and their NIRFI was collected by
using a Kodak multimodal imaging system IS2000MM with an excitation at 625 ±
20 nm and an emission at 700 ± 35 nm. The PhD monomers were obtained by
dissolve PhD molecules in good solvent (DMSO).
Photothermal and photodynamic effects of pPhD NPs. For photothermal effect
evaluation, pPhD NPs with different concentrations (1, 5, 10 and 50 µM) were
placed in 96-well plate, and treated with 0.4W cm−2 laser (680 nm) for 3 min.
Water solution was set as control (0 µM), and treated with identical laser exposure.
The hyperthermia produced by pPhD NPs were monitored by a FLIR thermal
camera. The photodynamic effect of pPhD NPs was indicated by the level of laser-
triggered ROS. The ROS production was visualised by a commercial probe, singlet
oxygen sensor green (SOSG). Similar to photothermal effect analysis, different
concentrations of pPhD NPs were incubated with SOSG probe, and exposed under
laser (680 nm, 0.4W cm−2) for 3 min. SOSG probe incubated with water was set as
blank control by treated with same laser dose. The fluorescence readouts of SOSG
was monitored by a microplate reader (SpectraMax M2, Molecular Devices) to
indicate the photodynamic effect that elicited by photosensitizer-harboured pPhD
NPs.
LC-MS analysis of the cleavage of hydrazone bond in PhD monomer. The triple
quadrupole LC-MS/MS system consisted of a 1200 series HPLC system (Agilent
Technologies, USA) and a mass spectrometer (6420 triple Quad LC/MS, Agilent
Technologies, USA). Chromatographic separation was carried out on a Waters
XBridge-C18 (2.1 mm × 50 mm, 3.5 μm) column at 40 °C with 10 mM ammonium
acetate 0.1% formic acid aqueous solution mobile as phase A and acetonitrile as
mobile phase B. 10 µL, 100 µM pre-treated PhD monomers (at pH 5.0 for over-
night) were injected into C18 column. The gradient was gradually changed from
10% mobile phase B (90% phase A) to 90% mobile phase B (10% phase A) within 9
min. The MS parameters were as follows: capillary, 5000 V; gas temperature, 320 °
C; gas flow, 8 mL per minute; and nebuliser, 40 psi. The data analysis was per-
formed by Mass Hunter Workstation Software Qualitative Analysis (Version
B.06.00) and Quantitative Analysis (Version B.05.02).
Accumulated drug release of pPhD NPs triggered by acidic pH and laser. 100
µM pPhD NPs were prepared and loaded into dialysis cartridges (MWCO is 3,500
Da) to determine the accumulated drug release profile. The cartridges were sub-
merged into 1000 mL PBS (pH 7.4) and acidized PBS (pH 5.0) respectively, and
stirred with a moderate-speed at ambient temperature. The laser-triggered drug
release was conducted by irradiation with laser at 0.4W cm−2 for 3 min before the
dialysis. The DOX remained in the dialysis cartridge was drawn with a micro-
syringe at various time points, and quantitatively measured by the UV–vis
absorbance of DOX. Each value was reported as the means of the triplicate samples.
Cell line. The human oral squamous cell carcinoma cells (OSC-3) line was kindly
courtesied from Dr. Kit S. Lam’s lab. Cell line authentication was performed by
short tandem repeat DNA profiling. The cell line has been tested for mycoplasma
contamination routinely. Cell culture was performed in a cell incubator (5% carbon
dioxide and 10% humidity. Temperature is 37 °C). The cells were cultured in
RPMI-1640 medium with 10% FBS and antibiotics containing penicillin and
streptomycin.
Cell viability assay. Human oral squamous cell carcinoma cells (OSC-3) were
seeded in 96-well plate with a density of 6000 cells per well. The cells were incu-
bated overnight until fully attached. Then the cells were treated with different
concentrations of various drug formulations. After 12 h treatments, the cells were
washed, and fresh medium was added. For the light treated groups, the cells were
exposed to the light for 3 min, and further incubated for another 24 h in parallel
with non-light treated groups. The cell viability was measured by MTT assay.
Results were shown in form of average cell viability [(ODtreat-ODblank)/(ODcontrol-
ODblank) × 100%] of triplicate wells.
Cell uptake assay. Since the fluorescence of Phy and DOX were both quenched in
pPhD NPs, the cell uptake of pPhD NPs may not be accurately measured if the
measurements were conducted under the aqueous circumstance. To evaluate the
cell internalisation of pPhD NPs and their post-transformed counterparts (pre-
treated with pH 6.8 to achieve size/charge dual-transformability). pPhD NPs and
post-transformed pPhD NPs were incubated with OSC-3 cells for 3 h, respectively,
and then the cells were detached and collected in a vial. After removing the
medium, the OSC-3 cells were dissolved with the same volume of DMSO to dis-
solve the cells and completely dissolved all materials that related to pPhD NPs. The
solutions were then evaluated by fluorescence spectrometer to test the fluorescence
of DOX. The DOX solution concentrations represent the cellular uptake of the
pPhD NPs. Each value was reported as the means of the triplicate samples.
ROS assay in cellular level. OSC-3 cells were seeded in 6-well plates with 5.0 ×
105 cells per well, and cultured for 24 h until fully attached. The cells were treated
with Phy, pPhD (pH 7.4) and pPhD (pH 6.8) for 3 h. The cells were then incubated
with DCF-DA (10 µM) for another 30-min followed by light treatment for 1 min
and analysis by flow cytometry (BD FACSCanto™ flow cytometry system). Cells
without any treatment were used as a control. The concentrations of all materials
were set as 10 µM.
Apoptosis assay. OSC-3 cells were seeded in 6-well plates with 5.0×105 cells per
well, and cultured for 24 h until all cells were fully attached. The cells were treated
with DOX, Phy, pPhD (pH 7.4) and pPhD (pH 6.8) for 3 h, then applied for light
treatment for 1 min. 24 h later, all cells were harvested and collected in EP tubes,
and washed twice (1000 rpm, 5 min, 4 °C) with cold PBS and then suspended in
100 µL binding buffer. Then, 5 µL Annexin V-FITC (20 µg/mL) was added to each
tube and incubated for 15 min at 4 °C in dark. After gentle vortex, 2 µL PI (50 µg/
mL) was added to each tube. The cells were filtered with Falcon™ Cell Strainers
prior to the flow cytometry analysis. The cells without any stain were set as negative
control. The concentrations of all materials were set as 10 µM.
Lysosomes colocalization assay. OSC-3 cells were incubated with 20 µM pPhD
NPs for 4 h, then stained with Lysotracker Deep Red for confocal laser scanning
microscopy (CLSM) observation. The fluorescence spectrum of Lysotracker Deep
Red overlapped with that of Phy, but the fluorescence readouts were much higher
than Phy under Cy5 channel. We, therefore, adjusted the parameters of CLSM until
we could not observe the fluorescence of Phy in pPhD NPs treated cells, and used
these parameters to observe the fluorescence of Lysotracker Deep Red to avoid the
interference of Phy. For DOX distribution, standard FITC channel was used.
Cell spheroids penetration of the nanoparticles. OSC-3 cells were seeded in the
round-shape bottom 96-well plate at a density of 104 cell per well. Cell spheroids
were treated with 20 µM pPhD (pH 7.4) and 20 µM post-transformed pPhD (pH
6.8). The penetrations of the nanoparticles were monitored by a confocal laser
scanning microscopy.
Phototherapeutic effect on cells. OSC-3 cells were seeded in 8-well chamber slide
with 5.0 × 104 cells per well, and cultured for 24 h until all cells were completely
attached. The cells were then treated with 10 µM pPhD NPs for 3 h. Cells without
any treatment were used as a control. Both treatments were exposed to light for 1
min. After light treatments, the OSC-3 cells were stained with 40 nM of DiOC6(3)
for 20 min to indicate the live cells, and propidium iodide (PI) for 20 min to label
the dead cells. Confocal laser scanning microscopy was employed to monitor the
photocytotoxicity to cells.
Pharmacokinetics evaluation. The jugular vein of male Sprague–Dawley rats was
cannulated, and a catheter was implanted for intravenous injection and blood
collection (Harland, Indianapolis, IN, USA). pPhD NPs (10 mg kg−1, calculated
based on the concentration of PhD monomer), upPhD NPs (10 mg kg−1) and free
DOX (4.7 mg kg−1) were i.v. administrated into rat (n= 3). The doses of free DOX
were equivalent to those in upPhD NPs and pPhD NPs groups, Whole blood
samples (~100 µL) were collected via jugular vein catheter before dosing and at
predetermined time points post-injection. The whole blood samples were then
centrifuged for serum collection, then the blood serum was diluted with DMSO
(20 µL serum was added to 80 µL DMSO) for fluorescence measurements. The
kinetics of free DOX was measured through testing the fluorescence of 591 nm
(excitation is 488 nm). For nanoformulation, the concentrations were measured by
testing the fluorescence of Phy (Ex= 412 nm and Em= 680 nm), because the
fluorescence of DOX was slightly quenched when conjugated to Phy. The values
were calculated by molar concentration first, then exchanged to mg per mL. The
values were plotted versus time after the subtraction of blood background.
Establishment of animal models and treatment schedule. Female athymic nude
mice (6 weeks old) were purchased from Harlan (Livermore, CA, USA). All animal
experiments were strictly in compliance with the guidelines of Animal Use and
Care Administrative Advisory Committee of University of California, Davis. The
subcutaneous tumour models were established by inoculated OSC-3 cells (5 × 106
cells per tumour) into both flanks of the nude mice. The orthotopic models were
established by inoculating OSC-3 (5 × 106 cells per mouse) to the lips of the mice.
After the subcutaneous tumours reached about 100 mm3 and orthotopic tumours
reached about 50 mm3, mice were divided into five groups (n= 6): control (PBS),
free drug (DOX), free photosensitizer (Phy), un-PEGylated PhD NPs (upPhD NPs)
and PEGylated PhD NPs (pPhD NPs). The mice received materials via i.v. injection
through the tail vein. The dose of DOX was 4.7 mg kg−1, Phy was 5.3 mg kg−1,
pPhD NPs were 10 mg kg−1(calculated based on the concentration of PhD
monomer) and upPhD NPs were 10 mg kg−1. The doses of free DOX and Phy were
equivalent to those in upPhD NPs and pPhD NPs groups. In subcutaneous models,
the right tumours were subjected to laser exposure (0.4W cm−2, 3 min), and the
left-side tumours were not treated with laser (to evaluate the efficacy of che-
motherapy). In the orthotopic models, all the tumours that treated with
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photosensitizer, including Phy, upPhD NPs and pPhD NPs, were treated with laser
(0.4W cm−2, 3 min). The laser treatments were introduced twice, at 24 h and 48 h
after the i.v. injection. During the laser treatments, the photothermal effects were
monitored and recorded by a FLIR infrared camera (FLIR Systems, Boston, MA).
In vivo ROS production. Orthotopic tumour-bearing mice were assigned into four
groups (n= 3): 1) PBS, 2) Phy, 3) upPhD NPs and 4) pPhD NPs. 5.3 mg kg−1 Phy,
10 mg kg−1 upPhD NPs and 10 mg kg−1 pPhD NPs (calculated based on the
concentration of PhD monomer) were i.v. administrated into mice respectively. 24
h later, tumours of the mice were irradiated with 0.4W cm−2 laser for 3 min. The
mice were sacrificed and the tumour was collected for NIRFI (Pre-cellROX). After
the NIRFI, the tumours were immediately sunk into ROS probe solution (Cell-
ROX) for 10 s, and conducted for another NIRFI (Post-cellROX). The in vivo ROS
production was presented by fluorescence intensities of Post-cellROX deducted the
fluorescence in Pre-cellROX tumours. The Phy signals were overlapped with
cellROX, we deducted the NIRF of Phy (Pre-cellROX) from the final imaging
results (Post-cellROX) to determine the ROS production.
Biodistribution of the nanoparticles. 10 mg kg−1 upPhD NPs and 10 mg kg−1
pPhD NPs (calculated based on the concentration of PhD monomer) were i.v.
administrated to orthotopic tumour-bearing mice respectively. The tumours were
then exposed to the laser at 24 h after the materials treatments. After the laser
trigger, whole body imaging was acquired at indicated time points. After in vivo
imaging, animals were sacrificed, and tumours and the major organs were har-
vested for ex vivo imaging.
In vivo performance of pPhD NPs monitored by MRI. For time-dependent
tumour accumulation measurement, the orthotopic tumour models were i.v.
injected with pPhD NPs (10 mg kg−1, calculated based on the concentration of
PhD monomer. Mn2+ dose: 0.01 mmol kg−1), and the tumour area was monitor by
a Bruker Biospec 7 T MRI scanner using T1-weighted Multi-Slice Multi Echo
(MSME) sequence with echo time (TE) of 14 ms and repetition time (TR) of
500 ms. The matrix size is 256×256, and the field of view (FOV) is 3.50 cm. For
monitoring the phototherapeutic effect, the OSC-3 tumour-bearing mice were
treated with pPhD NPs (i.v. injection, 10 mg kg−1), then the tumour site was
exposed under continuous laser (0.8W cm−2 for 3 min) at 24 h and 48 h after i.v.
injection. The tumour conditions were monitored by MRI in real-time with the
same parameters as that in tumour accumulation experiment. pPhD NPs doses
were calculated based on the concentration of PhD monomer.
Tissue penetration evaluation. 10 mg kg−1 NT-pPhD NPs and 10 mg kg−1 pPhD
NPs were i.v. injected into oral tumour-bearing mice, respectively. 24 h laser,
100 µL, 10 mgmL−1 FITC-dextran (70 k) were i.v. injected to stain the blood vessel
for 2 min. After that, the mice were sacrificed, the tumours were collected for cryo-
section. Then, the tissue slices were subjected to CLSM observation. The thickness
of slices was 20 µm. NT-pPhD NPs and pPhD NPs were both calculated based on
the concentrations of PhD monomers, the amounts of PEG were excluded. For
nanoparticles distribution, standard Cy 5 channel was used for observation of Phy;
For blood vessel, standard GFP channel was used.
Animal experiments for further investigation. The subcutaneous and orthotopic
oral cancer models were established by transplanting OSC-3 cells to two positions
of the flanks or lips of nude mice, respectively. After tumour developed at 15 days,
the mice were randomly assigned into different groups (n= 6) to receive the
treatments. The groups included control (PBS), PEGylated PhD NPs (pPhD NPs),
DOX nanoformulation (Doxil), non-transformable pPhD NPs (NT-pPhD NPs)
and pPhD NPs with low laser dose groups. All tumour-bearing mice were treated
once per week for 3 consecutive weeks by i.v. administration. In subcutaneous
models (mice bearing two tumours), the right tumours that treated with
photosensitizer-harboured materials were subjected to laser exposure (0.4W cm−2,
3 min, the pPhD NPs with low laser dose group receive a dose of 0.2W cm−2 for 6
min), and the left-side tumours were not treated with laser to evaluate the efficacy
of chemotherapy alone. In the orthotopic models, all tumours treated with
photosensitizer-harboured materials were treated with laser. The laser treatments
were given twice at 24 h and 48 h after the i.v. injection.
Tumour volume and body weight measurements. The body weights and tumour
sizes were monitored three times a week, and the tumour volume was calculated by
the following formula: Tumour volume= (Length ×Width ×Width)/2.
H&E evaluation. All laser-treated tumours were collected and stained with
hematoxylin and eosin (H&E) to evaluate the effect of phototherapy. The main
organs of each group, including heart, liver, spleen, lung, kidney, small intestine,
were collected for H&E assay to evaluate the toxicity of the materials.
Statistics. Data statistics were analysed by calculating the t-test between two
groups, and One-way ANOVA analysis of variations for multiple groups. Unless
otherwise noted, all results were expressed as the mean ± s.d. A value of p < 0.05
was considered statistically significant.
Data availability
All relevant data are included in the main manuscript and the Supplementary Infor-
mation. Additional data are available from the corresponding author upon reasonable
request.
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